Prab at 02:34, 29 June 2023

2023-06-29T02:34:04Z

New page

[[Piracetam]] is a synthetic derivative of the neurotransmitter gamma-aminobutyric acid (GABA) which is marketed in numerous global regions as a medication for conditions such as [[myoclonus]], and as a cognitive enhancer. However, the medical community's consensus on its efficacy is far from unified, as clinical trials and studies have produced varying outcomes.
[[File:Piracetam synthesis02.svg|Piracetam synthesis|thumb]]
== Medical Use ==
Piracetam has been indicated for use in a variety of neurological and cognitive conditions. Its primary approved use is for the treatment of cortical myoclonus, a type of involuntary muscle movement originating in the brain's cortex. Some researchers have also explored piracetam's potential as a [[nootropic]], or cognitive-enhancing agent, though these uses remain controversial.

== Mechanism of Action ==
The exact mechanism of piracetam remains unclear, but it is believed to modulate certain neurotransmitter systems and improve neuroplasticity. Despite being a GABA derivative, piracetam doesn't appear to interact with GABA receptors or influence GABA uptake or metabolism.

== Controversies and Limitations ==
The effectiveness of piracetam has been a subject of debate within the medical community. While some studies have demonstrated mild cognitive improvement in populations such as older adults or individuals with cognitive impairments, other studies have found negligible or no benefits. The heterogeneity of study designs and outcomes has made it difficult to draw definitive conclusions about the drug's effectiveness.

In the [[United States]], piracetam is not approved by the [[Food and Drug Administration]] (FDA) for any medical use, and is sold as a dietary supplement. This has raised concerns about the regulation, quality, and safety of piracetam products.

== Side Effects and Safety ==
Piracetam is generally well-tolerated, with reported side effects including nervousness, agitation, and gastrointestinal disturbances. However, the long-term safety profile of piracetam, especially as a cognitive enhancer in healthy individuals, is not well understood.
[[Category:Pharmacology]]
[[Category:Nootropics]]
{{stub}}
== References ==
<references/>
# "Piracetam: an old drug with novel properties?" Acta Pol Pharm. [http://www.actapol.net/pub/5_2_2004.pdf]
# "Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled crossover study." The Journal of Clinical Psychiatry. [https://pubmed.ncbi.nlm.nih.gov/16889450/]
# "Piracetam: a review of pharmacological properties and clinical uses." CNS Drug Reviews. [https://pubmed.ncbi.nlm.nih.gov/16007238/]
# "The 'nootropic' approach to the pharmacology of the ageing brain." Drugs Aging. [https://pubmed.ncbi.nlm.nih.gov/21936205/]
# "The misuse of prescription drugs: evidence from the distribution of consumption levels in the US population." Drug and Alcohol Dependence. [https://www.sciencedirect.com/science/article/abs/pii/S0376871618308022]

Piracetam - Revision history

Prab at 02:34, 29 June 2023